scholarly journals Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Hong Zhao ◽  
Qi Wang ◽  
Changling Luo ◽  
Ligai Liu ◽  
Wen Xie
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Antiviral Treatment ◽  
Research Data ◽  
Current Status ◽  
Evaluation Time ◽  
Long Term Prognosis ◽  
Time Evaluation

Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis. Effective antiviral treatment can significantly improve the long-term prognosis of decompensated patients, and some patients present recompensation of decompensated hepatitis B cirrhosis. At present, there are limited research data on the recompensation of decompensated hepatitis B cirrhosis. There is still controversy regarding the evaluation time, evaluation indicators, influencing factors, and long-term prognosis of recompensation.

Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective

2021 ◽  
Author(s):  
Yao-Chun Hsu ◽  
Cheng-Hao Tseng ◽  
Yen-Tsung Huang ◽  
Hwai-I Yang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Treatment ◽  
External Validation ◽  
Liver Stiffness ◽  
Current Status ◽  
Risk Scores ◽  
Essential Components

AbstractAccurate risk prediction for hepatocellular carcinoma (HCC) among patients with chronic hepatitis B (CHB) may guide treatment strategies including initiation of antiviral therapy and also inform implementation of HCC surveillance. There have been 26 risk scores developed to predict HCC in CHB patients with (n = 14) or without (n = 12) receiving antiviral treatment; all of them invariably include age in the scoring formula. Virological biomarkers of replicative activities (i.e., hepatitis B virus DNA level or hepatitis B envelope antigen status) are frequently included in the scores derived from patients with untreated CHB, whereas measurements that gauge severity of liver fibrosis and/or reserve of hepatic function (i.e., cirrhosis diagnosis, liver stiffness measurement, platelet count, or albumin) are essential components in the scores developed from treated patients. External validation is a prerequisite for clinical application but not yet performed for all scores. For the future, higher predictive accuracy may be achieved with machine learning based on more comprehensive data.

scholarly journals Long-term antiviral treatment improves hepatic fibrosis in chronic hepatitis B patients

2014 ◽  
Vol 22 (20) ◽  
pp. 2933
Author(s):  
Xue-Hua Yan ◽  
Xiao-Yong Chen ◽  
Bin-Hua Li ◽  
Jia-Li Li ◽  
Yuan-Zhi Ma
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatic Fibrosis ◽  
Antiviral Treatment

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

2020 ◽  
Vol 73 (5) ◽  
pp. 1037-1045 ◽  
Author(s):  
George V. Papatheodoridis ◽  
George N. Dalekos ◽  
Ramazan Idilman ◽  
Vana Sypsa ◽  
Florian Van Boemmel ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Caucasian Patients ◽  
Similar Risk
Sign in / Sign up

Export Citation Format

Share Document